MedTrace Logo

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

NCT01505296 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-12-16

No results posted yet for this study

Summary

The objective is to compare the progression of Atrial Fib (AF) burden by continuous monitoring in patients with recently diagnosed paroxysmal AF treated by catheter ablation (PVI) versus anti-arrhythmic drug (AAD) therapy.

Conditions

Interventions

DRUG

Antiarrhythmic drug

propafenone, flecainide, sotalol, dofetilide

PROCEDURE

Catheter ablation

Complete PVI

Sponsors & Collaborators

  • Biosense Webster, Inc.

    collaborator INDUSTRY

  • Valley Health System

    lead OTHER

Principal Investigators

  • Jonathan Steinberg, MD · Valley Health System

  • Evegny Pokushalou, MD · State Resarch Institute of Circulation Pathology, Novosibirsk, Siberia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01505296 on ClinicalTrials.gov